Syncom Formulations has accepted the resignation of Rahul Vijay Bankda as Chief Financial Officer, effective August 11, 2026. The company disclosed that Bankda is moving to a different professional responsibility within the organization, ensuring continuity of leadership without external recruitment. This internal transition suggests stability in financial oversight despite the change in title.

The resignation was received by the company on August 8, 2026, at 11:24 AM. The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s contributions during his tenure. The board noted that he will continue to be associated with the company in a different capacity.

Bankda stated in his resignation letter that the decision arises from his choice to undertake a new role within the organization. He explicitly confirmed that the resignation does not stem from any disagreement with the Board of Directors or management, nor is it attributable to any other material reason.

Regulatory Disclosure Details

The company made the disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Vaishali Agrawal, Company Secretary and Compliance Officer, signed the intimation to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 8, 2026. The company confirmed that all necessary statutory and regulatory formalities, including filings with the Registrar of Companies, are being completed.

Syncom Formulations has accepted the resignation of its founder, Kedarmal Shankarlal Bankda, from the offices of Whole-Time Director and Director, effective August 11, 2026. This leadership change marks the end of more than five decades of association for Bankda, who established the company and guided its growth into a WHO-GMP and ISO 9001:2015 certified entity. The resignation is voluntary and driven by health considerations and a strategic focus on succession planning, ensuring a smooth transition to the next generation of leadership without any disagreement with the Board or management.

The company received Bankda’s resignation letter on August 8, 2026, at 10:35 AM. In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Syncom Formulations filed the requisite disclosures with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). Vaishali Agrawal, Company Secretary and Compliance Officer, signed the disclosure documents.

Resignation Details

The resignation covers both the executive role of Whole-Time Director and the non-executive position of Director. Bankda’s DIN is 00023050. The cessation of his roles takes effect at the close of business hours on August 11, 2026.

In his resignation letter, Bankda described his tenure as an "enriching journey" that began with the vision of establishing the company. He emphasized that every enduring institution must embrace timely succession planning. He stated that while giving due importance to his health and well-being, he considers it appropriate to pass on executive responsibilities to new leadership capable of carrying forward the company's values and legacy.

Board Acknowledgement

The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s exceptional leadership and unwavering commitment. The Board noted that his vision and guidance played a significant role in the company's growth and development over the past five decades. The Board expressed sincere gratitude for his dedicated service and conveyed best wishes for his good health and future endeavors.

Bankda confirmed that his decision was entirely voluntary and did not arise from any material reason or conflict with stakeholders. He expressed confidence in the company's future under its capable leadership, affirming that Syncom Formulations will continue to achieve new milestones and create lasting value.